208 related articles for article (PubMed ID: 33650025)
21. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation.
Sorensen SV; Peng S; Monz BU; Bradley-Kennedy C; Kansal AR
Pharmacoeconomics; 2013 Jul; 31(7):589-604. PubMed ID: 23615895
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Operative Versus Nonoperative Management of Patients With Intra-articular Calcaneal Fractures.
Albin SR; Bellows BK; Van Boerum DH; Hunter S; Koppenhaver SL; Nelson RE; Marcus R; Dibble L; Cornwall M; Fritz JM
J Orthop Trauma; 2020 Jul; 34(7):382-388. PubMed ID: 31917759
[TBL] [Abstract][Full Text] [Related]
23. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
[No Abstract] [Full Text] [Related]
25. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
27. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
Congly SE; Varughese RA; Brown CE; Clement FM; Saxinger L
Sci Rep; 2021 Sep; 11(1):17787. PubMed ID: 34493774
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Open Versus Endoscopic Carpal Tunnel Release.
Barnes JI; Paci G; Zhuang T; Baker LC; Asch SM; Kamal RN
J Bone Joint Surg Am; 2021 Feb; 103(4):343-355. PubMed ID: 33591684
[TBL] [Abstract][Full Text] [Related]
29. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
[No Abstract] [Full Text] [Related]
30. Cost-Effectiveness Analysis of Nonoperative Management Versus Early Drilling for Stable Osteochondritis Dissecans Lesions of the Knee in Skeletally Immature Patients.
LeBrun DG; DeFrancesco CJ; Fabricant PD; Lawrence JTR
Arthroscopy; 2021 Feb; 37(2):624-634.e2. PubMed ID: 33271176
[TBL] [Abstract][Full Text] [Related]
31. Lifetime quality of life and cost consequences of delays in endovascular treatment for acute ischaemic stroke: a cost-effectiveness analysis from a Singapore healthcare perspective.
Ni W; Kunz WG; Goyal M; Ng YL; Tan K; De Silva DA
BMJ Open; 2020 Sep; 10(9):e036517. PubMed ID: 32948553
[TBL] [Abstract][Full Text] [Related]
32. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
[TBL] [Abstract][Full Text] [Related]
34. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
[TBL] [Abstract][Full Text] [Related]
35. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study.
Carta A; Conversano C
BMC Health Serv Res; 2021 Sep; 21(1):986. PubMed ID: 34537034
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.
Giannouchos TV; Mitsikostas DD; Ohsfeldt RL; Vozikis A; Koufopoulou P
Clin Drug Investig; 2019 Oct; 39(10):979-990. PubMed ID: 31302899
[TBL] [Abstract][Full Text] [Related]
37. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.
Whittington MD; Pearson SD; Rind DM; Campbell JD
Value Health; 2022 May; 25(5):744-750. PubMed ID: 35190252
[TBL] [Abstract][Full Text] [Related]
38. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
Kim HL; Kim KA; Choi GH; Jang ES; Ki M; Choi HY; Jeong SH
Clin Mol Hepatol; 2022 Jan; 28(1):91-104. PubMed ID: 34736311
[TBL] [Abstract][Full Text] [Related]
39. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
